Waning population immunity to measles in Taiwan

Vaccine

Volumn 30, Issue 47, 2012, Pages 6721-6727

  Chen, Chih Jung ^a,b   Lee, Ping Ing ^c   Hsieh, Yu Chia ^a,b   Chen, Po Yen ^d   Ho, Yu Huai ^e   Chang, Chee Jen ^f   Liu, Ding Ping ^g   Chang, Feng Yee ^g   Chiu, Cheng Hsun ^a,b   Huang, Yhu Chering ^a,b   Lee, Chin Yun ^c   Lin, Tzou Yien ^a,b  

^a CHANG GUNG CHILDREN S HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^e BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^f CHANG GUNG UNIVERSITY   (Taiwan)

^g CENTER FOR DISEASE CONTROL   (Taiwan)

Author keywords

Measles; Seropositive rate; Taiwan; Waning immunity

Indexed keywords

IMMUNOGLOBULIN G; MEASLES VACCINE;

ARTICLE; FEMALE; HUMAN; IMMUNITY; MAJOR CLINICAL STUDY; MALE; MEASLES; POPULATION RESEARCH; PRIORITY JOURNAL; SEROPREVALENCE; TAIWAN;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNITY, HERD; INFANT; MALE; MEASLES; MEASLES VACCINE; MIDDLE AGED; SEROEPIDEMIOLOGIC STUDIES; TAIWAN; YOUNG ADULT;

EID: 84867483656     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.05.019     Document Type: Article

References (26)

1. Peltola H., Jokinen S., Paunio M., Hovi T., Davidkin I. Measles, mumps, and rubella in Finland: 25 years of a nationwide elimination programme. Lancet Infect Dis 2008, 8:796-803.
2. Moss W.J., Griffin D.E. Measles. Lancet 2011, 10.1016/S0140-6736(10)62352-5.
3. Huang C.L., Yang Y.H., Wang L.C., Lin Y.T., Tsai Y.Y., Chiang B.L. Humoral and cellular immune response after measles vaccination in Taiwan. J Microbiol Immunol Infect 2005, 38:169-175.
4. Lee M.S., Chien L.J., Yueh Y.Y., Lu C.F. Measles seroepidemiology and decay rate of vaccine-induced measles IgG titers in Taiwan, 1995-1997. Vaccine 2001, 19:4644-4651.
5. Chiu H.H., Lee C.Y., Chih T.W., Lee P.I., Chang L.Y., Lin Y.J., et al. Seroepidemiological study of measles after the 1992 nationwide MMR revaccination program in Taiwan. J Med Virol 1997, 51:32-35.
6. Centers for Disease Control Taiwan. Notifiable infectious diseases statistics system, [accessed 07.11.11]. http://nidss.cdc.gov.tw/.
7. Cheng W.Y., Yang C.F., Hou Y.T., Wang S.C., Chang H.L., Chiu H.Y., et al. Imported measles and implications for its elimination in Taiwan. Emerg Infect Dis 2011, 17:1523-1526.
8. Chen J.H., Tsou T.P., Liu D.P. Measles resurgence in Taiwan-lessons learned. J Formos Med Assoc 2009, 108:267-269.
9. Dominguez A., Torner N., Barrabeig I., Rovira A., Rius C., Cayla J., et al. Large outbreak of measles in a community with high vaccination coverage: implications for the vaccination schedule. Clin Infect Dis 2008, 47:1143-1149.
10. Outbreak news Measles outbreaks in Europe. Wkly Epidemiol Rec 2011, 86:173-174.
11. Measles: United States, January-May 20. MMWR Morb Mortal Wkly RepV 60 2011, 666-668.
12. Ho T.S., Wang S.M., Wang L.R., Liu C.C. Changes in measles seroepidemiology of healthcare workers in southern Taiwan. Epidemiol Infect 2011, 14:1-6.
13. Katz S.L., Hinman A.R. Summary and conclusions: measles elimination meeting, 16-17 March 2000. J Infect Dis 2004, 189:S43-S47.
14. Hall R., Jolley D. International measles incidence and immunization coverage. J Infect Dis 2011, 204:S158-S163.
15. McQuillan G.M., Kruszon-Moran D., Hyde T.B., Forghani B., Bellini W., Dayan G.H. Seroprevalence of measles antibody in the US population, 1999-2004. J Infect Dis 2007, 196:1459-1464.
16. Fu C., Xu J., Liu W., Zhang W., Wang M., Nie J., et al. Low measles seropositivity rate among children and young adults: a sero-epidemiological study in southern China in 2008. Vaccine 2010, 28:8219-8223.
17. Progress toward the 2012 measles elimination goal-Western Pacific Region, 1990-2008. MMWR Morb Mortal Wkly Rep 2009, 58:669-673.
18. Tharmaphornpilas P., Yoocharean P., Rasdjarmrearnsook A.O., Theamboonlers A., Poovorawan Y. Seroprevalence of antibodies to measles, mumps, and rubella among Thai population: evaluation of measles/MMR immunization programme. J Health Popul Nutr 2009, 27:80-86.
19. Bautista-Lopez N., Ward B.J., Mills E., McCormick D., Martel N., Ratnam S. Development and durability of measles antigen-specific lymphoproliferative response after MMR vaccination. Vaccine 2000, 18:1393-1401.
20. Whittle H.C., Aaby P., Samb B., Jensen H., Bennett J., Simondon F. Effect of subclinical infection on maintaining immunity against measles in vaccinated children in West Africa. Lancet 1999, 353:98-102.
21. Parent du Chatelet I., Floret D., Antona D., Levy-Bruhl D. Measles resurgence in France in 2008, a preliminary report. Eurosurveillance 2009, 14(6).
22. Parker A.A., Staggs W., Dayan G.H., Ortega-Sanchez I.R., Rota P.A., Lowe L., et al. Implications of a 2005 measles outbreak in Indiana for sustained elimination of measles in the United States. N Engl J Med 2006, 355:447-455.
23. Xu J.X., Liang J.H., Tan H.F., Yun X.X. Epidemiological characteristics and control measures of measles in Guangzhou City during 2002-2005. J Trop Med 2007, 7:699-701.
24. Cook I.F. Sexual dimorphism of humoral immunity with human vaccines. Vaccine 2008, 26:3551-3555.
25. Klein S.L., Jedlicka A., Pekosz A. The Xs and Y of immune responses to viral vaccines. Lancet Infect Dis 2010, 10:338-349.
26. Davidkin I., Jokinen S., Broman M., Leinikki P., Peltola H. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up. J Infect Dis 2008, 197:950-956.